GOG-0229O
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Randomized Phase II with a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer NCT #01935973
Principal Investigator
Status
Terminated
Open to Accrual
December 23, 2013
Closed to Accrual
July 18, 2015
Closed to Accrual & Treatment
August 9, 2015
Terminated
April 10, 2020
Disease Site
Gynecologic [GY] Uterine Corpus
Phase
I
Developmental Therapeutics
No
Primary Objective
To assess the relative activity of trametinib (MEK inhibitor) alone or in combination with GSK2141795 (AKT inhibitor) for patients with recurrent or persistent endometrial cancer by progression-free survival.
Patient Population
Patients with recurrent or persistent endometrial cancer by progression-free survival.
Target Accrual
148
Protocol Document
Informed Consent
Tracked Amendments
Previous Protocol Versions
Previous Informed Consents
Study Memos
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
